Abstract：
UNASSIGNED: In light of the increasing importance of immunotherapy in bladder cancer treatment, this study is aim to investigate the expression and clinical significance of programmed cell surface death-1 (PD-1) in bladder cancer patients without lymph node metastasis, and to compare and analyze the difference of PD-1 in draining lymph nodes and tumor tissues.
UNASSIGNED: The expression of PD-1 on T cells and the proportion of positive PD-1 + T cells of IFN-γ and CD105a were detected by flow cytometry, and the correlation between PD-1 expression and clinical parameters was analyzed.
UNASSIGNED: The percentage of PD-1 positive cells in drainage lymph nodes was higher than that in tumor tissues (P < 0.001). PD-1 positive cells accounted for the highest proportion in CD3 + T cells. The proportion of IFN-γ-positive PD-1 + T cells in draining lymph nodes was significantly higher than that in tumor tissues (P < 0.001), while there was no significant difference in CD105a positive PD-1 + T cells between tumor tissues and draining lymph nodes. Pathological grade, tumor size and stage were positively correlated with PD-1 expression level in the lymph nodes.
UNASSIGNED: The high expression of PD-1 in patients with bladder cancer without lymph node metastasis, especially in draining lymph nodes, suggests that PD-1 may play a key role in the regulation of tumor immune microenvironment. The correlation between PD-1 and clinical parameters indicates its potential prognostic value. These findings provide important clinical implications for PD-1 targeted therapy, but further prospective studies are needed to determine the application value of PD-1 in therapeutic strategies.
UNASSIGNED: The expression of PD-1 on T cells and the proportion of positive PD-1 + T cells of IFN-γ and CD105a were detected by flow cytometry, and the correlation between PD-1 expression and clinical parameters was analyzed.
UNASSIGNED: The percentage of PD-1 positive cells in drainage lymph nodes was higher than that in tumor tissues (P < 0.001). PD-1 positive cells accounted for the highest proportion in CD3 + T cells. The proportion of IFN-γ-positive PD-1 + T cells in draining lymph nodes was significantly higher than that in tumor tissues (P < 0.001), while there was no significant difference in CD105a positive PD-1 + T cells between tumor tissues and draining lymph nodes. Pathological grade, tumor size and stage were positively correlated with PD-1 expression level in the lymph nodes.
UNASSIGNED: The high expression of PD-1 in patients with bladder cancer without lymph node metastasis, especially in draining lymph nodes, suggests that PD-1 may play a key role in the regulation of tumor immune microenvironment. The correlation between PD-1 and clinical parameters indicates its potential prognostic value. These findings provide important clinical implications for PD-1 targeted therapy, but further prospective studies are needed to determine the application value of PD-1 in therapeutic strategies.
摘要：
■鉴于免疫治疗在膀胱癌治疗中的重要性日益增加，本研究旨在探讨程序性细胞表面死亡-1(PD-1)在无淋巴结转移的膀胱癌患者中的表达及临床意义,并比较分析PD-1在引流淋巴结和肿瘤组织中的差异。
■流式细胞术检测T细胞上PD-1的表达以及IFN-γ和CD105a的阳性PD-1+T细胞的比例，并分析PD-1表达与临床参数的相关性。
■引流淋巴结中PD-1阳性细胞的百分比高于肿瘤组织（P<0.001）。CD3+T细胞中PD-1阳性细胞所占比例最高。引流淋巴结中IFN-γ阳性PD-1+T细胞的比例明显高于肿瘤组织(P<0.001),而CD105a阳性PD-1+T细胞在肿瘤组织和引流淋巴结之间没有显着差异。病理分级,肿瘤大小和分期与淋巴结中PD-1表达水平呈正相关。
■PD-1在无淋巴结转移的膀胱癌患者中高表达，尤其是在淋巴结引流中，提示PD-1可能在调节肿瘤免疫微环境中起关键作用。PD-1与临床参数之间的相关性表明其潜在的预后价值。这些发现为PD-1靶向治疗提供了重要的临床意义。但需要进一步的前瞻性研究来确定PD-1在治疗策略中的应用价值.
■流式细胞术检测T细胞上PD-1的表达以及IFN-γ和CD105a的阳性PD-1+T细胞的比例，并分析PD-1表达与临床参数的相关性。
■引流淋巴结中PD-1阳性细胞的百分比高于肿瘤组织（P<0.001）。CD3+T细胞中PD-1阳性细胞所占比例最高。引流淋巴结中IFN-γ阳性PD-1+T细胞的比例明显高于肿瘤组织(P<0.001),而CD105a阳性PD-1+T细胞在肿瘤组织和引流淋巴结之间没有显着差异。病理分级,肿瘤大小和分期与淋巴结中PD-1表达水平呈正相关。
■PD-1在无淋巴结转移的膀胱癌患者中高表达，尤其是在淋巴结引流中，提示PD-1可能在调节肿瘤免疫微环境中起关键作用。PD-1与临床参数之间的相关性表明其潜在的预后价值。这些发现为PD-1靶向治疗提供了重要的临床意义。但需要进一步的前瞻性研究来确定PD-1在治疗策略中的应用价值.
